Oppenheimer reaffirmed their hold rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report report published on Thursday morning.
Other analysts have also recently issued reports about the stock. Piper Jaffray Companies set a $125.00 target price on shares of Agios Pharmaceuticals and gave the company a buy rating in a research note on Thursday, August 2nd. ValuEngine lowered shares of Agios Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, September 11th. Needham & Company LLC reissued a buy rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. BidaskClub raised shares of Agios Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, September 27th. Finally, Guggenheim initiated coverage on shares of Agios Pharmaceuticals in a research report on Monday, September 17th. They issued a neutral rating on the stock. Six analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $96.27.
Shares of AGIO opened at $70.36 on Thursday. Agios Pharmaceuticals has a one year low of $51.62 and a one year high of $99.82. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of -10.42 and a beta of 2.04.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative return on equity of 48.51% and a negative net margin of 461.78%. The firm had revenue of $15.20 million during the quarter, compared to analyst estimates of $22.72 million. During the same quarter in the previous year, the business earned ($1.59) earnings per share. The business’s quarterly revenue was up 33.8% compared to the same quarter last year. Sell-side analysts predict that Agios Pharmaceuticals will post -6.2 EPS for the current year.
In other Agios Pharmaceuticals news, Director John Maraganore sold 13,555 shares of the business’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $72.75, for a total value of $986,126.25. Following the sale, the director now owns 38,609 shares of the company’s stock, valued at approximately $2,808,804.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction on Friday, October 5th. The shares were sold at an average price of $69.79, for a total transaction of $209,370.00. Following the completion of the sale, the insider now directly owns 53,932 shares in the company, valued at approximately $3,763,914.28. The disclosure for this sale can be found here. Insiders have sold 23,305 shares of company stock worth $1,734,343 in the last ninety days. 3.02% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Woodford Investment Management Ltd acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $32,849,000. Principal Financial Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 11.5% in the 1st quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock valued at $1,218,000 after purchasing an additional 1,533 shares in the last quarter. Barrett Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $253,000. Bank of New York Mellon Corp boosted its stake in shares of Agios Pharmaceuticals by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 212,733 shares of the biopharmaceutical company’s stock valued at $17,918,000 after purchasing an additional 6,169 shares in the last quarter. Finally, NewSquare Capital LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $182,000. 94.38% of the stock is currently owned by hedge funds and other institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Featured Article: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.